Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Tarsus Pharmaceuticals (NASDAQ: TARS) will report first quarter 2026 financial results on Wednesday, May 6, 2026 with a live webcast at 1:30 p.m. PT / 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus Pharmaceuticals (NASDAQ: TARS) will report first quarter 2026 financial results on Wednesday, May 6, 2026 with a live webcast at 1:30 p.m. PT / 4:30 p.m. ET. A recorded version will be posted to the company's website shortly after the call and archived for approximately 90 days.
Details
News Market Reaction – TARS
On Apr 30, the first trading day after this news, TARS closed 4.85% above the previous close.
Data tracked by StockTitan Argus for the Apr 30 session.
Key Figures
- Webcast time (PT)
- 1:30 p.m. PT
- Scheduled Q1 2026 results webcast on May 6, 2026
- Webcast time (ET)
- 4:30 p.m. ET
- Scheduled Q1 2026 results webcast on May 6, 2026
- Replay duration
- 90 days
- Recorded webcast archived on company website
Previous Earnings date Reports
-
Announced timing and webcast details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
| Media Contact: | |
| Adrienne Kemp | |
| Sr. Director, Corporate Communications | |
| (949) 922-0801 | |
| AKemp@tarsusrx.com | |
| Investor Contact: | |
| David Nakasone | |
| Head of Investor Relations | |
| (949) 620-3223 | |
| DNakasone@tarsusrx.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.